EBMT 2018 | CMV treatment for stem cell transplant recipients: antivirals

Genovefa Papanicolaou

Many infections can occur in cancer patients who are immunocompromised after receiving a stem cell transplant. In this interview, Genovefa Papanicolaou, MD, from Memorial Sloan Kettering Cancer Center, New York, NY, speaks about the current and future developments in the treatment of a particularly dangerous viral infection, cytomegalovirus (CMV). This interview was conducted at the 2018 European Group for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal.

Share this video